Telbivudine

Telbivudine C화학적 특성, 용도, 생산

개요

There are approximately 400 million people worldwide with chronic hepatitis B virus (HBV) infection, about onethird of whom have potentially progressive and life-threatening liver disease associated with the infection. Chronic hepatitis B infection can lead to cirrhosis, liver failure and hepatocellular carcinoma. Globally, HBV infection accounts for over one million deaths annually. At present, lamivudine and adefovir dipivoxil are the only approved nucleoside/ nucleotide analogs for the treatment of HBV infection. However, resistance to lamivudine is now recognized in 16 to 32% of HBV-infected patients after the first year of monotherapy and about 50% of patients after two years. With adefovir treatment, the resistance rate is much lower, at about 2.5% after two years of therapy. Experience in treating chronic HIV infections has proven the advantage of therapy with a combination of antiviral compounds. Similarly for HBV, there is a clear need for additional antiviral compounds. Several promising candidates are currently in clinical development. Idenix (then known as Novirio) discovered that the known beta-L-nucleosides, L-dA, L-dC (torcitabine) and L-dT (telbivudine), have highly specific activity against HBV. These L-nucleosides are essentially without activity against any of the other viruses tested and are similarly without effect in cell culture and in vivo toxicological tests. However, they are phosphorylated within human cells to their triphosphates which inhibit the HBV DNA polymerase,but not human polymerases. Of these three compounds, telbivudine was the only one to combine reasonable oral bioavailability with good anti-HBV activity and so was progressed to development jointly with Novartis with the highest priority.

용도

Antiviral (treatment of hepatitis B infection).

원료

After 1 year resistance occurred in 7–20% of patients on telbivudine depending upon past exposure to other drugs used in the treatment of hepatitis B and the type of infection. Development of resistance was less frequent in those receiving telbivudine than in those receiving lamivudine.

Pharmaceutical Applications

A synthetic thymidine nucleoside analog formulated for oral use in the treatment of chronic hepatitis B infection.

Pharmacokinetics

Oral absorption： 100%
C_max 600 mg/kg oral： 3.7 μg/mL
Volume of distribution： In excess of body water
Plasma protein binding：3.3%
It is eliminated renally, necessitating dose adjustment in patients with renal insufficiency. It should not be administered with pegylated interferon because of an increased risk of neuropathy.

Clinical Use

Treatment of chronic hepatitis B in patients >16 years of age

부작용

Adverse effects are similar to those of lamivudine and include upper respiratory tract infection, headache, fatigue and gastrointestinal upset. Myopathy and peripheral neuropathy are rare but have been observed in some patients several weeks into the course with associated rise in serum creatine kinase levels. Acute exacerbations of hepatitis have been observed on discontinuation of therapy. Lactic acidosis may occur, necessitating drug discontinuation.

Telbivudine 준비 용품 및 원자재

원자재

준비 용품

Telbivudine 공급 업체

공급자	전화	이메일	국가	제품 수	이점
SynZeal Research Pvt Ltd	--	standards@synzeal.com	India	6522	58
United States Biological	--	chemicals@usbio.net	United States	6256	80
Wuhan Kehaojia Biotechnology Co., Ltd.	--	2248475041@qq.com	CHINA	2650	58
Beijing Luyuan Bird Biotechnology Co., Ltd.	--	15810802415@139.com	CHINA	6757	58
Shanghai Weiwei Biological Technology Co., Ltd.	--	sales@wheybio.com	CHINA	4398	58
Shanghai Yubo Biotechnology Co., Ltd.	--	344843571@qq.com	CHINA	6322	58
Absin Bioscience Inc.	--	chenjw@absin.cn	CHINA	6661	58
Shanghai Yuqi Biological Technology Co., Ltd.	--	847627550@qq.com	CHINA	6087	58
Shanghai Hao Biological Technology Co., Ltd.	--	market@xlswkj.com	CHINA	6805	58
Shanghai Ziqi Biological Technology Co., Ltd.	--	2453006496@qq.com	CHINA	6192	58